


Orphan Disease Treatment Institute



Target : Orphan Disease Treatment Institute Co., Ltd.

Outline : Development of therapeutic agent for Duchenne muscular dystrophy with ENA oligonucleotides as the active ingredient

Authorized investment : ¥2,010 million (maximum)



- Make effective use of patents and technologies from academia that have fallen into "the devil's river" between baseline research and development research, and provide a bridge to pharmaceutical companies
- Provide momentum for Japanese pharmaceutical companies to become more aggressive in development of orphan drugs
- Pump-prime private VC investment in orphan drug technologies